Structure-activity relationships between the Aconitum C20- diterpenoid alkaloid derivatives and the growth suppressive activities of Non-Hodgkin's lymphoma Raji cells and human hematopoietic stem/progenitor cells

Investigational New Drugs

Volumn 29, Issue 1, 2011, Pages 1-8

  Hazawa, Masaharu ^a   Takahashi, Kenji ^a   Wada, Koji ^b   Mori, Takao ^c   Kawahara, Norio ^c   Kashiwakura, Ikuo ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

^c North Japan Chemical Inc   (Japan)

Author keywords

Aconitum C20 diterpenoid alkaloid; Hematopoietic stem progenitor cells (HSPC); Raji cells; Structure activity relationships (SAR)

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 11 ANISOYL PSEUDOKOBUSINE; 11 META TRIFLUOROMETHYLBENZOYL PSEUDOKOBUSINE; 15 ANISOYL PSEUDOKOBUSINE; 6 ANISOYL PSEUDOKOBUSINE; ALKALOID; ALKALOID DERIVATIVE; ANTINEOPLASTIC ALKALOID; CYCLIN DEPENDENT KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CD34 SELECTION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME PHOSPHORYLATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IC 50; LYMPHOMA CELL; METABOLIC INHIBITION; MINIMUM INHIBITORY CONCENTRATION; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RAJI CELL; STRUCTURAL HOMOLOGY; STRUCTURE ACTIVITY RELATION;

ACONITUM; ALKALOIDS; BLOTTING, WESTERN; BRIDGED COMPOUNDS; BUTADIENES; CARBON; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 2; DITERPENES; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; G1 PHASE; HEMATOPOIETIC STEM CELLS; HUMANS; LYMPHOMA, NON-HODGKIN; NITRILES; PHENANTHRENES; PHYTOTHERAPY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79151483676     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9327-4     Document Type: Article

References (22)

1. B Foroutan AA Ruf B Costall D Anderson 2007 An in vitro model to study chemoresistance in non-Hodgkin's lymphoma patients over-expressing mutant p53 J Pharmacol Toxicol Methods 55 151 158 1:CAS:528:DC%2BD2sXhvVyhs74%3D 10.1016/j.vascn.2006.05.008 16870476
2. AR Jazirehi XH Gan D Vos C Emmanouilides B Bonavida 2003 Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis Mol Cancer Ther 2 1183 1193 1:CAS:528:DC%2BD3sXovFCqtbw%3D 14617792
3. JS Johnston A Johnston MG Wientjes JL Au 2003 Synergy between 3-azido-3- deoxythymidine and paclitaxel in human pharynx FaDu cells Pharm Res 20 957 961 1:CAS:528:DC%2BD3sXkvFSlurs%3D 10.1023/A:1024431218327 12880279
4. FM Stewart D Temeles P Lowry T Thraves WW Grosh PJ Quesenberry 1993 Post-5-fluorouracil human marrow: stem cell characteristics and renewal properties after autologous marrow transplantation Blood 81 2283 2289 1:STN:280:DyaK3s3ksVChsg%3D%3D 8481510
5. CA White 1991 Rituximab immunotherapy for non-Hodgkin's lymphoma Cancer Biother Radiopharm 14 241 250
6. DW Blayney BW McGuire SE Cruickshank DH Johnson 2005 Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma Oncologis 10 138 149 1:CAS:528: DC%2BD2MXis1Kntro%3D 10.1634/theoncologist.10-2-138
7. M Fu M Wu Y Qiao Z Wang 2006 Toxicological mechanism of Aconitum alkaloids Pharmazie 61 735 741 1:CAS:528:DC%2BD28XhtVSjsrzE 17020146
8. 2+ homeostasis in the cardiac excitation-contraction coupling is a crucial mechanism of arrhythmic toxicity in aconitine-induced cardiomyocytes Biochem Biophys Res Commum 354 929 936 1:CAS:528:DC%2BD2sXhs1Sntrc%3D 10.1016/j.bbrc.2007.01.082
9. K Wada M Hazawa K Takahashi T Mori N Kawahara I Kashiwakura 2007 Inhibitory effects of diterpenoid alkaloids on the growth of A172 human malignant cells J Nat Prod 70 1854 1858 1:CAS:528:DC%2BD2sXhtlKru7nM 10.1021/np070270w 18044843
10. M Hazawa K Wada K Takahashi T Mori N Kawahara I Kashiwakura 2009 Suppressive effects of novel derivatives prepared from Aconitum alkaloids on tumor growth Invest New Drugs 27 111 119 1:CAS:528:DC%2BD1MXitVOmtbY%3D 10.1007/s10637-008-9141-4 18551247
11. SJ Hosseinimehr O Inanami T Hamasu M Takahashi I Kashiwakura T Asanuma, et al. 2004 Activation of C-Kit by Stem Cell Factor Induces Radioresistance to Apoptosis through ERK-dependent Expression of Survivin in HL60 cells J Radiat Res 45 557 561 1:CAS:528:DC%2BD2MXisFSiu78%3D 10.1269/jrr.45.557
12. J Chen HY Gu N Lu Y Yang W Liu Q Qi, et al. 2008 Microtubule depolymerization and phosphorylation of c-Jun N-terminal kinase-1 and p38 were involved in gambogic acid induced cell cycle arrest and apoptosis in human breast carcinoma MCF-7 cells Life Sci 83 103 109 1:CAS:528:DC%2BD1cXosVyisb8%3D 10.1016/j.lfs.2008.05.003 18586278
13. XM Liu LG Wang W Kreis DR Budman LM Adams 2001 Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells Br J Cancer 85 1403 1411 1:CAS:528:DC%2BD38XhsVeltg%3D%3D 10.1054/bjoc.2001.2107 11720482
14. S Yolanda A Donna DB Elena A Patricio 2009 Regulation of genistein-induced differentiation in human acute myeloid leukemia cells (HL60, NB4) Protein kinase modulation and reactive oxygen species generation Biochem Pharmacol 77 384 396 10.1016/j.bcp.2008.10.035
15. D Huang Y Ding WM Luo S Bender CN Qian E Kort, et al. 2008 Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo Cancer Res 61 81 88 10.1158/0008-5472.CAN-07-5311
16. GI Evan KH Vousden 2001 Proliferation, cell cycle and apoptosis in cancer Nature 411 342 348 1:CAS:528:DC%2BD3MXktVSjsr8%3D 10.1038/35077213 11357141
17. D Iizuka O Inanami A Matsuda I Kashiwakura T Asanuma M Kuwabara 2005 X irradiation induced the proapoptotic state independent of the loss clonogenic ability in Chinese hamster V79 cells Radiat Res 164 36 44 1:CAS:528: DC%2BD2MXlvFCrt70%3D 10.1667/RR3393 15966763
18. K Olga D Debopriya MH Laura B Sanchita S Doris G Rina, et al. 2009 Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition Cancer Res 69 565 572 10.1158/0008-5472.CAN-08-3389
19. JB Gibbs 2000 Mechanism-based target identification and drug discovery in cancer research Science 287 1969 1973 1:CAS:528:DC%2BD3cXhvFyruro%3D 10.1126/science.287.5460.1969 10720316
20. JB Gibbs 2000 Anticancer drug targets: growth factors and growth factor signaling J Clin Invest 105 9 13 1:CAS:528:DC%2BD3cXislSktA%3D%3D 10.1172/JCI9084 10619855
21. KW Ewa W Jaroslaw LM Ewa C Bernadetta H Jerzy F Irena, et al. 2008 Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group Cancer 113 367 375 10.1002/cncr.23558
22. T Robak P Smolewski B Cebula O Grzybowska-Izydorczyk JZ Blonski 2007 Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia Eur J Haematol 79 107 113 1:CAS:528:DC%2BD2sXpslKjsLo%3D 10.1111/j.1600-0609.2007.00889.x 17635235